DE60020352T2 - Zusammensetzung und Methode zur Inuzierung von Apptosis in Prostatakrebszellen mittels M-DNA und MCC - Google Patents

Zusammensetzung und Methode zur Inuzierung von Apptosis in Prostatakrebszellen mittels M-DNA und MCC Download PDF

Info

Publication number
DE60020352T2
DE60020352T2 DE60020352T DE60020352T DE60020352T2 DE 60020352 T2 DE60020352 T2 DE 60020352T2 DE 60020352 T DE60020352 T DE 60020352T DE 60020352 T DE60020352 T DE 60020352T DE 60020352 T2 DE60020352 T2 DE 60020352T2
Authority
DE
Germany
Prior art keywords
mcc
dna
prostate cancer
cells
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60020352T
Other languages
German (de)
English (en)
Other versions
DE60020352D1 (de
Inventor
C. Nigel PHILLIPS
C. Mario FILION
Stéphanie READER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telesta Therapeutics Inc
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of DE60020352D1 publication Critical patent/DE60020352D1/de
Application granted granted Critical
Publication of DE60020352T2 publication Critical patent/DE60020352T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60020352T 1999-04-01 2000-03-30 Zusammensetzung und Methode zur Inuzierung von Apptosis in Prostatakrebszellen mittels M-DNA und MCC Expired - Lifetime DE60020352T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12745199P 1999-04-01 1999-04-01
US127451P 1999-04-01
PCT/CA2000/000342 WO2000059518A2 (en) 1999-04-01 2000-03-30 Composition and method for inducing apoptosis in prostate cancer cells

Publications (2)

Publication Number Publication Date
DE60020352D1 DE60020352D1 (de) 2005-06-30
DE60020352T2 true DE60020352T2 (de) 2005-10-20

Family

ID=22430191

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60020352T Expired - Lifetime DE60020352T2 (de) 1999-04-01 2000-03-30 Zusammensetzung und Methode zur Inuzierung von Apptosis in Prostatakrebszellen mittels M-DNA und MCC

Country Status (10)

Country Link
EP (1) EP1165106B8 (https=)
JP (1) JP2002541114A (https=)
AT (1) ATE296106T1 (https=)
AU (1) AU780909B2 (https=)
CA (1) CA2366090C (https=)
CY (1) CY1107455T1 (https=)
DE (1) DE60020352T2 (https=)
ES (1) ES2238996T3 (https=)
PT (1) PT1165106E (https=)
WO (1) WO2000059518A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033879A1 (en) * 1998-12-04 2000-06-15 Bioniche Life Sciences Inc. Method for the treatment of inflammation
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법

Also Published As

Publication number Publication date
AU3413500A (en) 2000-10-23
DE60020352D1 (de) 2005-06-30
EP1165106B8 (en) 2005-07-27
WO2000059518A2 (en) 2000-10-12
JP2002541114A (ja) 2002-12-03
ATE296106T1 (de) 2005-06-15
WO2000059518A3 (en) 2001-02-01
CA2366090C (en) 2011-05-24
PT1165106E (pt) 2005-10-31
EP1165106A2 (en) 2002-01-02
EP1165106B1 (en) 2005-05-25
CA2366090A1 (en) 2000-10-12
ES2238996T3 (es) 2005-09-16
AU780909B2 (en) 2005-04-21
CY1107455T1 (el) 2012-12-19

Similar Documents

Publication Publication Date Title
DE3833319C2 (https=)
DE69826288T2 (de) Zelluläres vesikel 'exosome', seine herstellung und verwendung zur stimulierung einer immunantwort
DE69732225T2 (de) Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür
DE69332357T2 (de) Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapie
WO2023184038A1 (en) Mrna delivery method and composition thereof
EP2471548A1 (de) siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
DE69809561T2 (de) Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod
WO2006015560A1 (de) Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
EP1441755A2 (de) Topikale verwendung von cytokinen und/oder chemokinen zur behandlung von viralen oder mykotischen hauterkrankungen oder tumorerkrankungen
DE69431959T2 (de) Therapeutische abgabesysteme und verfahren für ihre verwendung
DE68905994T2 (de) Koloniestimulierungsfaktor-gelatinkonjugate.
DE69829316T2 (de) Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand
DE60020352T2 (de) Zusammensetzung und Methode zur Inuzierung von Apptosis in Prostatakrebszellen mittels M-DNA und MCC
DE3875859T2 (de) Zubereitungen zur verbesserung der adcc-therapien.
DE4310935A1 (de) Mikroemulsionen, deren Herstellung sowie Verwendung bei der Behandlung von Krebserkrankungen
US6794368B1 (en) Composition and method for inducing apoptosis in prostate cancer cells
WO2021174149A2 (en) Fidgetin-like 2 as a target to enhance wound healing
DE69919386T2 (de) Zusammensetzung zur behandlung von entzündungen
US20230321140A1 (en) Multiple mediators targeted multifunctional nanoparticles and uses thereof
DE202024104792U1 (de) Indolderivat-Formulierung für gezielte krebsbekämpfende Wirkung von Chemotherapeutika
CN120983390A (zh) 一种柚皮素载药体系及其制备方法和应用
DE10131148A1 (de) Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
US4877616A (en) Process for preparing xerosin II and xerosin III, improved biological response modifiers
DE19639811A1 (de) Verwendung einer Liposomenlösung zur Verstärkung der Wirksamkeit und/oder Verminderung der Toxizität von Arzneimitteln
RU2351322C1 (ru) Фармацевтический препарат для местного и наружного применения на основе низкомолекулярного индуктора интерферона

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: READER, STEPHANIE, QUEBEC, CA

Inventor name: FILION, C., MARIO, MONTREAL, CA

Inventor name: PHILLIPS, C., NIGEL, POINT-CLAIRE, CA

8364 No opposition during term of opposition